VIGL Stock Overview
A clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vigil Neuroscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$10.22 |
| 52 Week Low | US$2.47 |
| Beta | 1.95 |
| 11 Month Change | 35.35% |
| 3 Month Change | 31.38% |
| 1 Year Change | -52.03% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.59% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate
May 30
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
Feb 01Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
Oct 14Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation
Jun 27Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation
Mar 14Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation
Nov 29Vigil draws bullish view at Wedbush on upcoming readout for lead asset
Sep 16Vigil Neuroscience announces $75M PIPE financing
Aug 12We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely
Jul 25Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?
Apr 10Shareholder Returns
| VIGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.9% | 1.0% | -0.2% |
| 1Y | -52.0% | 10.7% | 22.9% |
Return vs Industry: VIGL underperformed the US Biotechs industry which returned 10.7% over the past year.
Return vs Market: VIGL underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| VIGL volatility | |
|---|---|
| VIGL Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VIGL's share price has been volatile over the past 3 months.
Volatility Over Time: VIGL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 65 | Ivana Magovcevic-Liebisch | www.vigilneuro.com |
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial.
Vigil Neuroscience, Inc. Fundamentals Summary
| VIGL fundamental statistics | |
|---|---|
| Market cap | US$142.07m |
| Earnings (TTM) | -US$82.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs VIGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIGL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$82.78m |
| Earnings | -US$82.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VIGL perform over the long term?
See historical performance and comparison